Clinical Trials Directory

Trials / Unknown

UnknownNCT01745874

Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging

Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment

Status
Unknown
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
University of Lausanne Hospitals · Academic / Other
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether whole-body MRI (WB-MRI) accuracy is superior to FDG-PET-CT considered as the gold-standard for the staging of distant lesions of rectal cancer.

Detailed description

Rectal cancer is the second cause of mortality after lung cancer in industrialized countries and represent 28% of colorectal carcinomas. Despite major improvements in diagnosis and treatment made those last years,mortality and morbidity remains high, because of high prevalence of metastasis and local recurrence. A accurate initial staging is of paramount importance for an appropriate treatment (neoadjuvant chemiotherapy and radiotherapy, surgery). Actually, there is no international consensus concerning imaging for the staging of rectal cancer and modalities used are variable from one center to another. WB-MRI represented a attractive and promising technique for the staging of rectal cancer, free of ionizing radiation .

Conditions

Timeline

Start date
2012-10-01
Primary completion
2013-10-01
Completion
2013-10-01
First posted
2012-12-10
Last updated
2012-12-10

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01745874. Inclusion in this directory is not an endorsement.